Bioxyne Limited (BXN) AI Stock Analysis

• Market Cap: AU$80.36M
• Dividend Yield: N/A
• Average Volume (3M): 5.47M
• Price to Earnings (P/E): 15.0
• Beta (1Y): 1.34
• Revenue Growth: 204.87%
• EPS Growth: N/A
• Country: AU
• Employees: 16
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): <0.01
• Shares Outstanding: 2,171,828,600
• 10 Day Avg. Volume: 4,635,579
• 30 Day Avg. Volume: 5,473,025
• PEG Ratio: -0.13
• Price to Book (P/B): 7.54
• Price to Sales (P/S): 2.90
• P/FCF Ratio: 22.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 68 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

Bioxyne Limited's strong financial performance, characterized by impressive revenue growth and improved profitability, is the most significant factor driving the stock score. The technical analysis indicates a neutral to slightly bearish trend, while the valuation suggests the stock is reasonably priced. The absence of earnings call data and corporate events means these factors do not influence the score.

Bioxyne Limited Business Overview & Revenue Model

Company Description

Bioxyne Limited, a life sciences and health products company, researches, develops, markets, and distributes dietary supplement and beauty products. It perates in two segments, Wholesale Sales and Direct Sales. The company engages in developing various functional foods and beauty products. Its products portfolio includes Progastrim for Gut and Immune Health; Progastrim plus Vitamin C for cold symptoms; and proTract for atopic dermatitis (eczema) for infants. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.

How the Company Makes Money

Bioxyne Limited makes money through the sale of its health and wellness products, which are distributed through various channels, including retail and direct-to-consumer platforms. The company's revenue streams are predominantly derived from its proprietary probiotic formulations and functional food products. Bioxyne has strategic partnerships and distribution agreements that help expand its reach in international markets, contributing significantly to its earnings. Additionally, the company invests in research and development to innovate and expand its product offerings, thereby driving sales growth and market presence.

Bioxyne Limited Financial Statement Overview

Summary

Bioxyne Limited exhibits strong financial performance with significant revenue growth and improved profitability. The company maintains a stable balance sheet with low leverage and high return on equity. Cash flow management has improved substantially, supporting the company's growth trajectory. Continued focus on enhancing gross margins and sustaining cash flow growth will be key to long-term success.

Income Statement

Bioxyne Limited has shown impressive revenue growth of 77% in the latest year, indicating strong market demand and expansion. The company has improved its profitability significantly, with a net profit margin of 16.1% and an EBIT margin of 16.8%, reflecting effective cost management and operational efficiency. However, the gross profit margin of 34.3% suggests room for improvement in production or procurement processes.

Balance Sheet

The balance sheet is solid with a low debt-to-equity ratio of 0.13, indicating conservative leverage and financial stability. The return on equity is high at 41.95%, showcasing effective use of shareholders' funds to generate profits. However, the equity ratio is not explicitly calculated, which could provide further insight into the company's financial structure.

Cash Flow

Bioxyne Limited has demonstrated a remarkable turnaround in cash flow, with free cash flow growth of 3473.2%, highlighting improved cash generation capabilities. The operating cash flow to net income ratio of 0.74 and free cash flow to net income ratio of 0.62 indicate strong cash conversion efficiency. Despite these strengths, maintaining consistent cash flow growth will be crucial for sustaining financial health.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	30.42M	30.42M	9.33M	5.16M	463.64K	2.11M
Gross Profit	10.45M	10.45M	3.40M	343.13K	-224.10K	639.71K
EBITDA	5.34M	5.34M	-13.03M	-1.88M	-463.30K	-425.93K
Net Income	4.90M	4.90M	-13.33M	-1.94M	-494.02K	-495.73K
Balance Sheet
Total Assets	20.90M	20.90M	6.70M	17.69M	445.59K	2.68M
Cash, Cash Equivalents and Short-Term Investments	7.67M	7.67M	1.03M	3.85M	65.93K	1.60M
Total Debt	1.53M	1.53M	673.72K	558.61K	397.39K	47.46K
Total Liabilities	9.53M	9.53M	3.40M	2.69M	810.43K	744.75K
Stockholders Equity	11.68M	11.68M	3.61M	15.14M	-364.84K	1.88M
Cash Flow
Free Cash Flow	3.86M	3.86M	-4.05M	-897.92K	-566.88K	19.47K
Operating Cash Flow	6.28M	6.28M	-3.56M	-841.28K	-506.81K	53.13K
Investing Cash Flow	-2.07M	-2.41M	-492.66K	4.10M	26.61K	-33.66K
Financing Cash Flow	2.42M	2.76M	1.21M	805.36K	493.24K	-46.78K

Bioxyne Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BXN, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.05, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.53 is Neutral, neither overbought nor oversold. The STOCH value of 62.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BXN.

Bioxyne Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLV	69 Neutral	AU$113.56M	16.19	10.07%	2.19%	38.25%	361.54%
BXN	68 Neutral	AU$80.36M	15.00	61.21%	―	204.87%	―
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
EVE	45 Neutral	AU$8.62M	―	-60.84%	―	-18.70%	20.83%
MBH	45 Neutral	AU$19.48M	―	-31.14%	―	-15.07%	29.50%
HCT	43 Neutral	AU$30.15M	35.65	―	―	6.76%	―
WNX	41 Neutral	€15.74M	―	-184.71%	―	39.53%	49.99%

Bioxyne Limited Corporate Events

Bioxyne Limited Releases Forward-Looking Financial Projections

Bioxyne Limited has released a presentation containing forward-looking statements regarding its future financial performance and market trends. The company emphasizes that these projections are subject to change due to various risks and uncertainties, and stakeholders should not rely solely on these statements for investment decisions. The presentation is not an offer or solicitation for securities and is intended for informational purposes only.

Bioxyne Limited Achieves Record Revenue and Expands into German Market

Bioxyne Limited reported a record quarterly revenue of $9.5 million, marking a 204% increase from the previous year and a 33% rise from the previous quarter. The company also achieved positive cash flow from operating activities and exceeded its FY25 revenue guidance. A significant development is their entry into the German market through a €3.2 million manufacturing and supply agreement, which is expected to strengthen their operations in the EU/UK region. The company is poised for further growth with additional contracts anticipated in Europe and the UK.

Bioxyne Limited Announces Positive Outlook for FY2026

Bioxyne Limited has announced a Business Update Webinar to discuss its Q4 2025 results and provide a positive outlook for FY2026. The company anticipates growth through expansion in Australia and entry into new markets such as the UK, Germany, and other EU countries. This strategic move is expected to strengthen Bioxyne’s market position and offer new opportunities for stakeholders.

Bioxyne Limited Announces Director’s Shareholding Adjustment

Bioxyne Limited announced a change in the director’s interest, with Mr. Anthony Ho disposing of 1,500,000 ordinary shares valued at $43,500 through an on-market sale and reallocation between accounts. This change reflects a strategic adjustment in the director’s holdings, potentially impacting investor perceptions and market dynamics for Bioxyne’s securities.

Bioxyne Limited Announces Director’s Share Disposal

Bioxyne Limited has announced a change in the interest of its director, Mr. Anthony Ho, involving the disposal of 1,500,000 ordinary shares valued at $43,500. This transaction, which involved an on-market sale and reallocation between accounts, reflects a strategic adjustment in the director’s holdings, potentially impacting investor perceptions and the company’s market dynamics.

Bioxyne Limited Releases Business Update and Progress Report

Bioxyne Limited has released a business update and progress report, highlighting its ongoing developments and strategic positioning in the pharmaceutical industry. The presentation emphasizes the company’s commitment to innovation and market expansion, although it contains forward-looking statements that are subject to change. Stakeholders are advised to consider the inherent risks and uncertainties associated with these projections.

Bioxyne Limited Expands into German Cannabis Market with €3.2 Million Agreement

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has entered the German cannabis market by securing a manufacture and supply agreement worth €3.2 million (A$5.6 million) with Farmakem d.o.o. and Adrex Pharmaceuticals GmbH. This agreement involves supplying a minimum of 1,600 kg of GMP-certified medical cannabis flower, with the first delivery scheduled for September 2025. The German medical cannabis market is rapidly growing, and Bioxyne’s entry is expected to bolster its growth in FY2026, leveraging its GMP certification for competitive advantages in Germany and other European markets.

Bioxyne Limited Secures GMP Compliance to Boost Global Expansion

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has received GMP compliance certificates under Mutual Recognition Agreements with several countries, including the UK, Canada, and the EU. This certification supports Bioxyne’s strategy to expand its global presence, particularly in European markets, and positions the company for growth in FY2026 as it enters new high-growth markets such as the UK and Germany.

Bioxyne Limited Prepares for Growth with Strategic Market Expansion

Bioxyne Limited is set to host a Business Update Webinar to discuss its FY2025 revenue guidance and market performance in Australia, the UK, and the EU. The company anticipates continued growth in FY2026, driven by its expansion into high-growth markets such as the UK and Germany. This strategic positioning is expected to enhance Bioxyne’s market presence and offer promising opportunities for stakeholders.

Bioxyne Limited Upgrades FY2025 Revenue Guidance Amid Strong Growth

Bioxyne Limited has upgraded its full-year FY2025 revenue guidance to $28 million, reflecting significant growth driven by its Australian pharmaceutical manufacturing and supply operations. The company reported a 267% increase in revenue for the first half of FY2025 and anticipates continued expansion in FY2026, particularly in Australia, the UK, Germany, and other EU markets. Bioxyne’s subsidiary, Breathe Life Sciences, leads the Australian market in manufacturing medicinal cannabis, MDMA, and Psilocybin products, contributing to the company’s robust performance. The company is also advancing its MDMA capsules into commercial production, positioning itself for long-term success in the growing psychedelic drugs market.